Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007486
Abstract: Key Points • JAK2, ABL, and MAPK signaling drive adaptive resistance to FLT3 inhibitors.• Polypharmacological targeting of FLT3, JAK2, ABL, and MAPK signaling provides a durable response in AML. read more here.
Keywords: flt3 inhibitors; adaptive resistance; jak2 abl; targeting flt3 ... See more keywords
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14174315
Abstract: Simple Summary Despite the recent approval of some FLT3 inhibitors by drug regulatory agencies, treatment guidelines for FLT3-mutated AML still require allogeneic transplantation as a necessary procedure to treat the disease in first or second… read more here.
Keywords: flt3 inhibitors; present future; resistance; resistance flt3 ... See more keywords